Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Arslan Tsai"'
Autor:
Ching-Yao Tsai, Chien-Liang Wu, Cheng-Kuo Cheng, Yun-Dun Shen, Wen-Chuan Wu, Pei-Chang Wu, Arslan Tsai, Jiann-Torng Chen
Publikováno v:
BMC Ophthalmology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background The Ranibizumab AMD Clinical Efficacy Study (RACER) conducted in treatment-naive adult Taiwanese patients with neovascular age-related macular degeneration (nAMD) suggested the importance of early and intensive dosing of ranibizum
Externí odkaz:
https://doaj.org/article/86876a1393fa475cbc00ee759189466d
Autor:
Ling Yeung, Chi-Chun Lai, San-Ni Chen, Cheng-Kuo Cheng, Chung-May Yang, Yi-Ting Hsieh, Arslan Tsai, Chang-Hao Yang
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Polypoidal choroidal vasculopathy (PCV) is a distinctive type of neovascular age-related macular degeneration prevalent in many Asian countries. However, there is still some controversy in how the subtypes of PCV are classified. This post-ho
Externí odkaz:
https://doaj.org/article/e9d5bca02b8c40ecb7b9b5a7a841f401
Autor:
Cheng-Kuo Cheng, Yi-Ting Hsieh, Ling Yeung, Chung-May Yang, Arslan Tsai, Chang-Hao Yang, San-Ni Chen, Chi-Chun Lai
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Polypoidal choroidal vasculopathy (PCV) is a distinctive type of neovascular age-related macular degeneration prevalent in many Asian countries. However, there is still some controversy in how the subtypes of PCV are classified. This post-hoc study r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af3e36dd2445da04cd9e7fa605eb0785
https://doi.org/10.1038/s41598-020-80731-1
https://doi.org/10.1038/s41598-020-80731-1
Autor:
Jiann-Torng Chen, Cheng-Kuo Cheng, Yun-Dun Shen, Wen-Chuan Wu, Arslan Tsai, Chien-Liang Wu, Ching-Yao Tsai, Pei-Chang Wu
Publikováno v:
BMC Ophthalmology
Background The current National Health Insurance scheme in Taiwan reimburses 3 initial plus 4 additional injections of ranibizumab 0.5 mg for eligible patients with neovascular age-related macular degeneration (nAMD). The Ranibizumab AMD Clinical Eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9304e2033eeba6c5d1d425cb446b69
https://doi.org/10.1186/s12886-020-01715-3
https://doi.org/10.1186/s12886-020-01715-3